Organigram Tables C$561m Aurora Bid, Blowing Curaleaf Out of the Water
Organigram offered C$7.80 per share (C$561m total) for Aurora Cannabis, topping Curaleaf's bid. Aurora's board recommends accepting. Organigram's offer includes cash and shares, backed by BAT. Deal needs shareholder and regulatory approvals, expected to close in January 2027. Combined entity would be a top Canadian cannabis company with global operations.
How this was made
The 30-second read
Why it matters
The new bid likely shifts market sentiment away from Curaleaf toward Organigram and Aurora, with possible price volatility for all parties involved.
Market read
The announcement represents a major consolidation move in the cannabis industry with immediate pricing implications for the four listed entities.
What to watch
Potential antitrust scrutiny in Canada and Europe, and the impact of BAT's capped voting rights on governance.
Background
The article details a competitive M&A battle for Aurora Cannabis, highlighting the financial structure and strategic rationale behind Organigram's superior offer.
Ticker impact
Aurora Cannabis (ACB) received a higher C$7.80 per share bid from Organigram, superseding Curaleaf's hostile offer.
downward pressure on Curaleaf (CRLF) as its bid is outcompeted; upside for Aurora (ACB) and Organigram (OGR.TO).
The new bid is 21% above Curaleaf's offer and backed by BAT financing, making Aurora's acceptance probable.
British American Tobacco (BTI) is providing a C$187.5m private placement to fund Organigram's cash component and will own a 42% stake post‑deal.
minimal immediate impact; long‑term upside if the combined cannabis entity succeeds.
BTI's stake is a financing move rather than a direct earnings driver.
Market effects
Consolidation in the Canadian cannabis sector could reshape market share and pricing dynamics.
European cannabis footprint expands, potentially influencing EU‑GMP regulatory environment.
Creates the largest publicly traded Canadian cannabis company, affecting global cannabis investment flows.
Counterpoint
If regulatory approvals stall, the deal could collapse, leaving Aurora vulnerable to a renewed Curaleaf bid.
Key entities
- companyAurora Cannabis
Target of the acquisition, currently listed on TSX/NYSE as ACB.
- companyOrganigram Global
Bidder offering C$7.80 per share, listed on TSX as OGR.
- companyBritish American Tobacco
Provides financing and will hold a significant stake post‑deal, ticker BTI.
- companyCuraleaf Holding
Current hostile bidder, listed on NASDAQ as CRLF.
